Staphylokinase

Staphylokinase — a thrombolytic agent developed by ThromboGenics — has successfully completed Phase II clinical trials. Staphylokinase could be used in cardiovascular disease to dissolve blood clots, which are responsible for causing acute myocardial infarction (AMI), or heart attack. A thrombolytic agent with efficacy similar to tPA, and with a significantly lower price, could be of substantial importance in advancing the standard of care for patients receiving thrombolytic therapy.

Partnership on THR-100

We entered into a license agreement with Bharat Biotech International Limited (India) in December 2006. The terms of the agreement cover manufacturing, clinical development, and commercialization. Under the terms of the agreement, we will receive double-digit royalties on net sales and Bharat Biotech will assume responsibility for all future costs.

Partnership on THR-174

Data from preclinical studies suggest that this second-generation staphylokinase may have potential to provide an even better efficacy and safety profile and, most importantly, reduced immunogenic response compared to earlier versions of staphylokinase and some other earlier established thrombolytics such as streptokinase. This means that THR-174 could potentially be administered to patients more than once, allowing treatment of subsequent cardiac events and improving quality of care.

We have completed a license agreement with Rhein Minapharm (Egypt) for the production, clinical development, and commercialization of THR-174 in the Middle East, Africa, and other countries. In return for granting this license, we will receive upfront and milestone payments and will earn double-digit royalties on net sales, while Rhein Minapharm will assume responsibility for all future costs.